The Growing Prevalence of Headaches to Drive the Growth of the Cluster Headache Syndrome Industry during the Forecast Period 2022-2027

Cluster Headache Syndrome Market Size is estimated to reach $512.3 million by 2027 and is poised to grow at a CAGR of 6.1% over the forecast period of 2022-2027. The growing number of cases of cluster headaches is driving the growth rate of the Cluster Headache Syndrome industry during the forecast period of 2022-2027. According to NCBI, up to 0.1% of the population is susceptible to the primary headache disease known as cluster headache. Cluster headache bouts can last anywhere between 15 and 180 minutes and occur up to 8 times per day for the patients. Studies in the fields of neuroimaging, clinical practice and experimentation have improved our knowledge of the pathophysiology of cluster headaches. Such growing Cluster Headache Syndrome Market research aids the growth of the Cluster Headache Syndrome Market.

During the projected period of 2022–2027, the rising incidence of depression is a significant element influencing the growth rate of the Cluster Headache Syndrome market. High alcohol consumption, changes in eating or sleeping habits and sedentary lifestyles are risk factors that increase the frequency of depression and further contribute to headaches. Additionally, during the forecast period of 2022–2027, emotional stress connected to family, friends, job or education is anticipated to accelerate the market's development rate. According to WHO, an estimated 3.8% of the world's population suffers from depression, including 5.0% of adults and 5.7% of persons over the age of 60. Around 280 million individuals worldwide suffer from depression which can influence the growth rate of the Cluster Headache Syndrome Market.

The increase in healthcare spending, which helps to improve its infrastructure, is a crucial element influencing the growth rate of the market for Cluster Headache Syndrome. According to WHO, global health spending increased steadily, reaching US$ 8.3 trillion, or 10% of global GDP between 2000 and 2018. The market dynamics would be further impacted by various government organizations’ efforts to strengthen the healthcare infrastructure by boosting funding.

In May 2021, Eli Lilly & Company proposes to increase the size of its Indiana industrial footprint by spending $2.1 billion on two new production facilities at Indiana's LEAP Lebanon Innovation and Research District in Boone County. These new facilities demonstrate Lilly's commitment to expanding its portfolio of potentially life-changing treatments by extending its production network.

The major companies in the Cluster Headache Syndrome Market include Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd and Novartis AG.

In June 2019 Dr. Reddy's Laboratories, an Indian multinational pharmaceutical firm, signed an asset purchase deal with Upsher-Smith, an American generics company, in June 2019 to transfer the rights to its two neurology medications, Zembrace and Tosymra. These medications are used to treat migraine and cluster headaches, respectively. They can be given orally, topically, intravenously and in other ways.